Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts

Affiliations

• ¹ Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany. uwe.platzbecker@medizin.uni-leipzig.de.
• ² MDS Unit, AOU Careggi, University of Florence, Florence, Italy.
• ³ Moffitt Cancer Center, Tampa, FL, USA.
• ⁴ Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA.
• ⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
• ⁷ Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
• ⁸ Bristol Myers Squibb, Princeton, NJ, USA.
• ⁹ Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris, France.